ARS Pharmaceuticals, a San Diego CA-based pharmaceutical company, raised $55M in Series D funding.
The round was led by SR One with participation from RA Capital Management and Deerfield Management. As part of this funding, ARS appointed Rajeev Dadoo, Ph.D., managing partner of SR One, and Peter Kolchinsky, Ph.D., managing partner and founder of RA Capital to the board of directors.
Led by Richard Lowenthal, founder, chief executive officer and president, ARS Pharmaceuticals is developing Neffy™ (ARS-1), an intranasal epinephrine spray with absorption technology for patients and ones at-risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis. is dedicated to empowering at-risk patients and caregivers to protect themselves from severe allergic reactions potentially leading to anaphylaxis.
The company intends to use the funds to advance Neffy™ through approval, to support initial launch activities, and to evaluate it in clinical studies for additional indications.